CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 51 enrolled
Drug / intervention
Ticagrelordrug
Likely dose
Ticagrelor 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03092076
NCT03092076Phase 1Completed
CompareCT.gov

The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese

Guangdong Provincial People's Hospital·interventional·Posted Mar 27, 2017·Updated Mar 27, 2017

In Brief

A Phase 1 clinical trial evaluating Ticagrelor for Healthy. Completed, enrolled 51 participants.

Detailed Summary

This study is a open and single center clinical trial in healthy Chinese.The objective of the study is to clarify the pharmacokinetics characteristics and antiplatelet effects of ticagrelor in Chinese and to investigate the impact of genotype.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 27, 2017
Enrollment StartMay 20, 2015
Primary CompletionOct 24, 2015
Study CompletionJun 16, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.3 years ago

Interventions

Ticagrelordrug

180 mg loading dose